Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics
Background: This study aimed to determine the association of estrogen receptor (ER) and programmed death ligand-1 (PD-L1) expression with the clinicopathological characteristics of type 1 endometrial cancer. Materials and methods: A total of 85 patients with type 1 endometrial cancer who underwent s...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294223000886 |
| _version_ | 1797387826763923456 |
|---|---|
| author | Setyo Teguh Waluyo Brahmana Askandar Tjokroprawiro Anny Setijo Rahaju |
| author_facet | Setyo Teguh Waluyo Brahmana Askandar Tjokroprawiro Anny Setijo Rahaju |
| author_sort | Setyo Teguh Waluyo |
| collection | DOAJ |
| description | Background: This study aimed to determine the association of estrogen receptor (ER) and programmed death ligand-1 (PD-L1) expression with the clinicopathological characteristics of type 1 endometrial cancer. Materials and methods: A total of 85 patients with type 1 endometrial cancer who underwent surgery at the Dr. Soetomo Hospital, Surabaya, Indonesia were retrospectively studied. Data about the age, menopausal status, body mass index, disease stage, cell differentiation, angiolymphatic invasion, myometrial invasion, and adjuvant therapy of the patients were collected from medical records. Immunohistochemistry with ER and PD-L1 antibodies was performed on all samples. The association between ER and PD-L1 expression and clinicopathological characteristics was statistically analyzed. Results: The positivity rates of ER and PD-L1 in type 1 endometrial cancer were 68.2 % and 78.5 %, respectively. ER positivity was significantly correlated with body mass index (BMI) ≥25, premenopausal status, early stage of disease, <1/2 myometrial invasion, negative nodal metastasis, and lack of adjuvant therapy. It was also associated with age <55 years, low-grade cells, and angiolymphatic invasion, but the correlation was not significant. Meanwhile, PD-L1 positivity was significantly correlated with BMI <25, menopausal status, advanced stage of disease, high-grade cells, angiolymphatic invasion, and adjuvant therapy. It was also associated with age ≥55 years and nodal metastasis, but the correlation was not significant. Conclusion: ER and PDL-1 positivity is associated with the clinicopathological characteristics of type 1 endometrial cancer. |
| first_indexed | 2024-03-08T22:31:42Z |
| format | Article |
| id | doaj.art-ce694c4097624e7493be05b0bb6ee3e1 |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-03-08T22:31:42Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-ce694c4097624e7493be05b0bb6ee3e12023-12-18T04:24:43ZengElsevierCancer Treatment and Research Communications2468-29422023-01-0137100766Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristicsSetyo Teguh Waluyo0Brahmana Askandar Tjokroprawiro1Anny Setijo Rahaju2Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Subspecialist Education Program, Dr Soetomo General Academic Hospital, Medical Faculty – Universitas Airlangga, Surabaya, IndonesiaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, Indonesia; Corresponding author.Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital/Universitas Airlangga Hospital, Surabaya, IndonesiaBackground: This study aimed to determine the association of estrogen receptor (ER) and programmed death ligand-1 (PD-L1) expression with the clinicopathological characteristics of type 1 endometrial cancer. Materials and methods: A total of 85 patients with type 1 endometrial cancer who underwent surgery at the Dr. Soetomo Hospital, Surabaya, Indonesia were retrospectively studied. Data about the age, menopausal status, body mass index, disease stage, cell differentiation, angiolymphatic invasion, myometrial invasion, and adjuvant therapy of the patients were collected from medical records. Immunohistochemistry with ER and PD-L1 antibodies was performed on all samples. The association between ER and PD-L1 expression and clinicopathological characteristics was statistically analyzed. Results: The positivity rates of ER and PD-L1 in type 1 endometrial cancer were 68.2 % and 78.5 %, respectively. ER positivity was significantly correlated with body mass index (BMI) ≥25, premenopausal status, early stage of disease, <1/2 myometrial invasion, negative nodal metastasis, and lack of adjuvant therapy. It was also associated with age <55 years, low-grade cells, and angiolymphatic invasion, but the correlation was not significant. Meanwhile, PD-L1 positivity was significantly correlated with BMI <25, menopausal status, advanced stage of disease, high-grade cells, angiolymphatic invasion, and adjuvant therapy. It was also associated with age ≥55 years and nodal metastasis, but the correlation was not significant. Conclusion: ER and PDL-1 positivity is associated with the clinicopathological characteristics of type 1 endometrial cancer.http://www.sciencedirect.com/science/article/pii/S2468294223000886ClinicopathologyEstrogen receptorPD-L1 expressionEndometrial cancer |
| spellingShingle | Setyo Teguh Waluyo Brahmana Askandar Tjokroprawiro Anny Setijo Rahaju Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics Cancer Treatment and Research Communications Clinicopathology Estrogen receptor PD-L1 expression Endometrial cancer |
| title | Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics |
| title_full | Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics |
| title_fullStr | Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics |
| title_full_unstemmed | Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics |
| title_short | Estrogen receptor and programmed death ligand-1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics |
| title_sort | estrogen receptor and programmed death ligand 1 expression in type 1 endometrial cancer and its associated clinicopathological characteristics |
| topic | Clinicopathology Estrogen receptor PD-L1 expression Endometrial cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2468294223000886 |
| work_keys_str_mv | AT setyoteguhwaluyo estrogenreceptorandprogrammeddeathligand1expressionintype1endometrialcanceranditsassociatedclinicopathologicalcharacteristics AT brahmanaaskandartjokroprawiro estrogenreceptorandprogrammeddeathligand1expressionintype1endometrialcanceranditsassociatedclinicopathologicalcharacteristics AT annysetijorahaju estrogenreceptorandprogrammeddeathligand1expressionintype1endometrialcanceranditsassociatedclinicopathologicalcharacteristics |